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Biochemical basis of the cardiotsxieity af Vx 
Wcccivcd 4 Felxwry I99 I 
Scrincqxxitic re;lgcatr, an\iehulincstcruae orgnnophuwphtarux compounds like Vx provoke, in the mieramahrr r:rngo, dipii&+likc vrntrieuhrr nr- 
rylhmiPs al’ non-chalincrgic origin in rodent hrtrrrr. The arnsifivicirs uf Ihc two r:it cardiac Nu’ ,K”-A’I’Posc is&xn~z (q und P:) RI Vx (O.l-IflO 
/rM) were mendurcd in xarcolcmmn vcsiclca. At I ,rM Vx, the inhibitian of the fotnl activity uvcrtlycd 18% bur never execcdcd 75~5 with I00 /IM, 
When the a) iaoform rietivity W:N inhihitcd by O,l ~rhl au&tCn, 11 wuo 3% inhibited by I rrM Vx, i.e. II 16&45 inhibition al the lute1 ueliviry, 
The cardiac cti bein8 related to the digittilisr.indrrccd toxicity, its aclcetivc inhibition by II micromolnr daw of Vx fully acc:enunra for the citrdiatoxieily 
ufVx. lnrxmuch 11s Vx hiid no cllkcr an (he mt kidney aI, di&rentklly innetivured the r:lrdiPe iruxymcx und apcifieully rcnetcd with aerinc? rerliducs, 
the putative binding&c(s) aT the arg:tnophoxphorux compound on rhe Nu”,K’-ATPuse molceuler hrrx bscn cnnaidcrcd. 
1, INTRODUCTION 
Organophosphorus compounds are known to irrevce- 
sibly inhibit cholinesterases by reacting with serinc 
residues [I]. They induce central and peripheral 
disorders resulting from their anticholinergic action. 
Cardiotoxicity was reported to involve a brief and in- 
tense sympathetic discharge, followed by an extreme 
parasympathetic one [2]. A third phase, in which vcn- 
tricular premature complexes and ventricular tachycar- 
dia occurred, was described in clinical reports [2,3]. 
Similar ventricular arrhythmias have been observed 
following administration of the organosphosphorus 
compound S-(2-diisopropylan~inoethyl)-O-ethylmcthyl- 
phospho-nothiolate (Vx) in either conscious or 
anaesthetized rats (12 pg/kg body weight s.c.) and dogs 
(3-6 pg/kg body weight s.c.) [4,6]. 
A recent electrophysiological work [7] in guinea-pig 
papillary muscles howed that Vx (5 FM) modified the 
course of the action potential. Depolarizing oscillations 
in resting membrane potential, so-called delayed 
afterdepolarizations, were recorded and, in some cases, 
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led CO the dcvelopmcnt of triggered activity in this non- 
automatic preparation. Moreover, these Vx-induced cF- 
fects were found to increase when the electrical stimula- 
tion frequency applied to the preparation was incrcas- 
ed, Such actions are classically reported [S] to charac- 
terize a digitalis-induced ventricular toxicity. 
inasmuch as a micromolar dose of Vx induced a 
digitalis-like toxicity in animals, the initial goal of this 
study was to determine whether or not this compound 
could inhibit the cardiac Na*,K”‘-ATPase activity, i.e. 
the pharmacological receptor for digitalis 191. In a se- 
cond aproach, we have looked for an either general or 
selective action of this compound on the cardiac and 
renal Na*,K*-ATPase isozymes. Then, in order to ap- 
proach what could be the molecular basis of the Vx ef- 
fects, the distributions of serine residues in the isoform- 
specific zones of the two enzyme molecules have been 
compared. 
Molecular cloning and sequence of the CY subunit en- 
coding DNAs revealed the existence of three major (Y 
subunit isoforms in rat: LYI, cr2 and a3 [lo]. In adult rat 
heart, the first two isoforms are expressed [ 11,123, 
At the membrane level of cardiac muscles of rat 
[13,14], guinea-pig [l§] and dog [lci], two functional 
Na*,K’-ATPase isoforms (so-called LYI and ~49) have 
been described. The ~9 isoform shows a high affinity 
for cardiac glycosides (apparent KJ values from 1 to 20 
r&l) and is resporislbie for their positive inotropic pro- 
perties. The ~1 isoform is of low affinity for digitalis 
(apparent & values from 0.3 to 7 PM). In rat and 
145 
guinerqig hearts, CTI inhibition by high doses (3r 
digitalis leads ta barb insrropie and toxic &&rs. 
Qur study show that Vx induced n selective inhibition 
(lf the cardiac QI isaform at a micramslar ranycl, 
wherews the cardiac ~YY isafarm was affected at higher 
VX dose% 
2. MATERIAL,. AND METW0BS 
Cmdiad aarcolcmmal rcfi;dlcX were ivelatcd rtrcordiny to aur 
prerlourly published proc+xlurc [It] drum nnrmal Wklar rtdnlt rtlt 
hc4:rts pdtd by n Cu”“4r6x wolutlnn [I3)* Kttt kltlnry 
Nn’,K’4TPaac was partinIly puriricd ~wtlexcribetl by Swcntlncr (IfI), 
Bnxymc activltirs were mearurcd at 37% 0% 0 function al time and 
umountr of proteins (from &I to 2ag), The rclnrionxhipli were linear. 
The enrym.stic assays were curried out with vc~islca pcrmrabilixed by 
LDS or SDS (lithium or xodium dodecyl ruli%o) trentmcnts (0.21) mg 
dctcrgenr/m~ of prateinn for 30 min at 20°C). The Na’“,K”-ATPctre 
activity was dctermincd using the coupled nssny method as prevloudy 
described [IQj, In the mlorosomal fractions, the xpceific nstivitlas of’ 
the Nn’,K”-ATPose varied from 60 to 90 pmal of irtarynnic 
phosphate liberated per rng of protein per hour, The ouabrin- 
invcnritire nctivity, mcastrrcd in the presence of 2 rnM ounbitin, nc- 
counted for less than 30% of the tanI ATPnsc activitica. 
Ln order ro restrict tlrc nmplitudc of the temperature ttnd 11mc. 
dependent dennturntionn of Vx cluring the asriays, all the cnzymutir: 
mcasurcmcnts have been carried out at 30% and did not exceed 20-22 
min. After a S-mitt preinrubarion of the reaction medium at 30°C, the 
enzymatic reaction was initinrcd by successive and rapid ndditions of 
Vx nnd LDS- {or SDS-) created membrnncs and continuously 
monitored far up IO 22 min. The inhibition lcvcl induced by a single 
dose of Vs remained stable during 22 min, In the assays, the mifx- 
imum final concentmtionr of digitalis rcccptors (i,e. 
Na*,K”-ATFeses) varied from 0.01 to I IN, with rcspcctive final 
concentrations of drug varying from 0, I to IOOrrM. Inhibition pcrcen- 
tagcs of the total activity were wlcula~etl by compnring the activities 
in the presence or absence of drug after correcting for the ounbnin- 
insensitive ATPasc activity. 
3. RESULTS AND DISCUSSION 
The organophosphorus Vx, was solubilized into 
methylethylketone. This solvent interacted with the en- 
zyme system at concentrations higher than 0.3% (v/v). 
In all the assays the vehicle concentrations never ex- 
ceeded 0.1% (v/v), and the maximum Vx concentration 
was 100pM. 
The organophosphorus compound did not affect the 
ouabain-insensitive ATPase activity or the coupling en- 
zymes (pyruvate kinase and lactodehydrogenase) (un- 
published). When tested on the total Na’,K+-ATPase 
activity, Vx was found to achieve a stable inhibition 
within 90 s. Indeed, this effect did not vary from 90 s to 
22 min (the longest kinetic period used). Thus, once 
bound, Vx would not be released. 
As shown in Table I, no inhibition of the cardiac 
Na” ,K”-ATPase activity was found with 0.1 ,&I Vx. 
The percentage of inhibition increased from 18 -+ 6% up 
to 75% between 1 and 100,&l Vx in the assay, This in- 
hibitory effect is consistent with previous reports show- 
ing an action of this type of compound on brain [20] 
and rat cardiac [al] Na’,K*-ATPase activities. 
146 
T&k I 
III rat cardiac sarcolemma vesicles, the proportionrrl 
conItibutions of the PTI plus N3 isoform activities in the 
total Nn” ,K’“-ATPase activity were 45 f 8% and 
S5 * 8%, respectively [13,19]. 
In order to determine whether VX had either a s&c- 
tivc or a specific effect on one of’ the two cardiac 
Na*,K*-ATPasc isoenzymes, LYI and/or ry2, the respon- 
siveness to Vx has been studied in the presence of 0.1 
@I ouabain. At this ouabain concentration, 90% of the 
activity drlc to the ~1 isoform was inhibited (IC& = 10 
nM) whereas no detectable effect could be found on the 
activity associated with the 01 isoform (Go=7 PM), 
Consequently, in the presence of 0.1 /rM ouabain, the 
activity due to the isoform LYI represented more than 
86070 of the rota1 activity measured. 
In rhe presence of this submaximal ouabain concen- 
tration, the association process of Vx to its site(s), the 
stability of the complex and its apparent irreversibility 
were indistinguishable from those found when assaying 
the Na”,K’-ATPase activity in the absence of ouabain, 
As shown in Table I (right panel), 0.1 /dM Vx did not 
induce any inhibition whereas a stable inhibition 
(35rt401o) was found with 1 ,dvi Vx. There was a sharp 
increase in the inhibition, from 0% to 35% between 0.1 
and 1 PM Vx whereas at a lOO-fold higher concentration 
(100 PM), Vx induced a 20% increase in the inhibition 
of the activity associated with ~1. There was no ap- 
parent relationship between the development rate of the 
inhibitory process, the Vx concentration and the 
isoform considered. 
The inhibition of cq did not exceed 61 Oto (Table I), It 
is very unlikely that the non-inhibited activity repre- 
sented LYI activity trapped into impermeable vesicles and 
inaccessible to Vx. Indeed, this isoform, to be assayed, 
should also be freely permeable to all the ligands of the 
enzyme. Furthermore, all Na+,K+-ATPase assays have 
been carried out with permeabilized ( etergent-treated) 
vesicles. An alternative xplanation would be that the 
Vx-resistant activity was of non-muscle origin. This 
possibility also has to be ruled out: only a few percent 
of our sarcolemmal vesicles isolated from normal rat 
heart were of non-muscle origin 1171. 
The percentage of inhibition of ~1 found with 1 @I 
VX fully accounts for the 18 f 6% inhibition of the total 
~riviry QTable t and Fig. E). Indeed, 33% inhibitian al 
al x4$% rantribution represents a lB% inhibltien crE 
the coca1 Nw”,K”=ATPtlsr! nctiviry. CI~X wanid nor bt! in- 
hibircd ac 1 &4 Vx. AC higher Vx keels, nn was more 
and more inhibiccd (Fig. 1). AC 100&I Vx, rhe maxi- 
mum inhibition found,, 75%1 of chc total accivicy would 
repretcnc rhe sum: 25% (SSrrlp ~45%) due to WI plus 
5@% (7%25%) due Wn;l, The iacrer isoform was almost 
completely inhibited: %I% (5Q%/S5%). 
The present study Cifi\if~ kWa that the digitalis-like 
cardistoxicicy, of non.cholineryie: origin, induced by a 
micromoirci~iar dose of Vx was due to a selective inhibi- 
cion of the cardiac CTI isoform of the! Nn”,K’-ATPasc. 
tnhibicion by cardiac glycosidcs of this isoform CYI of 
low affinity for ounbain also led to toxic effcccs in rat 
as wcii as in guinea-pig, Note that, at a Vx dose 5-fold 
lower than chc toxic one [7], we already observed a 
significant (35%) inhibition of the (YI isoform, 
The relatively high sensitivity of the cardiac QY( iso- 
forrrt ICI Vx was not observed with the rat kidney (YI 
isoform; Vx (up to 30&I) did not inhibit this activity 
(data not shown), 
A comparison of the amino acid scquenccs of the two 
LY subunits of the Na9,K”~ATPasc as presented by [ 10) 
provides a basis to determine, at the protein level, which 
part(s) of the moleculr might be involved in these dif- 
ferent reactivities to Vx, The prediction is that regions 
of the mokculc chat vary in serinc composition from (YI 
Vx concentrations Q.&l) 
Fig. 1. Respective inhibitions by Vx of the two active rat cardiac 
Na”,K*-ATPa% isoenzymes ry) (RI) and (YZ, (0) The percentages of 
inhibition of ~1 were calculated from the values given in Table 1 (right 
panel) and assuming that the CYI isoform activity represented 45% of 
the total enzymatic activity. The percentages of q inhibition were the 
differences between the inhibitions of total activity and the (~1 inhibi- 
tions. 
iaafclrm co (~2 are reglerno imporcnnc in’ terms of sen- 
sitivicy ce, Vx, 
8ur aFthe idencicai XW~EO of a ~ubunlt isoferrm swur- 
curex [10,22,23], the regions with the greatest sequence 
variations Iihowiny iraform4prcific: ktwrcs, 86 defined 
by [23], occurred in clusters, in chc NWz-rcrminst half, 
in the excrltccllular Ioop HSH2 imgli~nced in ouwbain 
binding [24] and near the fluorescein isothioeysnete 
(FtSCZ)-rrascive sire [23]. Seven positions of serine only 
occurred in the &I isaform and ac least one‘ of them 
should account for the higher apparent sensitivity co 
Vx, It is not yet possible to ?i~y whechcs all 7 scrine 
residues concriblrtc co chc sclecrivicy, although a prc- 
dominant role of this that adjoins the nueieocide- 
binding site seems likely, 
A particular reactivity of’ a single scrine could fully 
account for the Vx/at isoform interactions. Indeed, the 
magnitude of chc art inhibition did not. significantly in- 
crease when [Vx] varied from 1 to 1OObtM (Fig. 1) suy- 
gcsring a limited number of serines involved in the 
chemical reaction with Vx. Furthermore, the kidney CYI 
isoform, very similar co the cardiac one, was not in. 
hibiced by Vx. 
So far, the simplest interpretation would be that the 
binding of Vx to PI occurred at a single site near, but 
not intrinsic to, the conserved sites essential for activity. 
According to this hypothesis, the serinc-494 near the 
ATP-binding site (FITGrcactive site) would be a good 
candidate since there are significant sequence variations 
in QI and cx2 isoforms in the variable region to the left 
of the FITC-reactive lysine, mainly regarding the serine 
residues. However, it is noteworthy that these com- 
parisons and suggestions suppose that rat brain and car- 
diac 1~1 isoforms displayed the same amino acid se- 
quences. This has not, as yet, been demonstrated. 
The incomplete inhibition of the CYI activity might be 
explained assuming that RI was heterogeneous and con- 
sisted of two forms, one responsible for the inotropic 
effect of high doses of ouabain [25] and insensitive to 
Vx and one responsible for the toxic effects of digitalis 
and sensitive to Vx. However, we have not been able yet 
co physically separate these putative two forms in 
hearts. 
The responsiveness of the cardiac cy2 isoform clearly 
differed from that of CXI (Fig. 1). The LYZ inhibition 
sharply increased with Vx concentrations suggesting a
successive recruitment of several a2-specific serine 
residues. The high concentrations of Vx necessary to in- 
hibit this isoform (up to 100 ,LN) reflect the low sen- 
sitivity of the reacting site(s) consistent with the general 
inhibitory effects of different organophosphorous 
compounds (diisopropylfluoridate, paraoxon and para- 
thion) on various ATPases including the cardiac 
Ca2+-ATPases 1% i j , 
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